Article Text

Download PDFPDF

New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology
  1. Elżbieta Senkus
  1. Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdańsk, Poland
  1. Correspondence to Dr Elżbieta Senkus; elsenkus{at}gumed.edu.pl
  • Therapy

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests honoraria: AstraZeneca, Novartis, Pfizer, Pierre Fabre, Roche travel expenses: AstraZeneca, Novartis, Pfizer, Roche.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.